SanegeneBio has entered a global licensing agreement with Genentech, part of the Roche Group, granting the pharmaceutical company exclusive worldwide rights to develop and commercialize one of its RNA interference (RNAi) therapeutic programs. The deal highlights growing industry investment in gene-silencing technologies aimed at treating a wide range of diseases.
Under the terms of the agreement, SanegeneBio will conduct early-stage development work before Genentech assumes responsibility for later clinical trials, regulatory activities and commercialization. Financially, the arrangement includes a $200 million upfront payment to SanegeneBio, along with potential development and commercial milestone payments worth up to $1.5 billion and tiered royalties on future product sales if the therapy reaches market.
RNA interference therapies work by selectively silencing disease-causing genes, preventing harmful proteins from being produced in the body. The approach has gained increasing attention in recent years as advances in delivery technologies have improved the ability to target tissues safely and effectively. SanegeneBio’s proprietary platform combines novel chemistry and delivery methods designed to enable the creation of small interfering RNA (siRNA) medicines across multiple therapeutic areas.
Company founder and CEO Weimin Wang said the partnership validates the company’s differentiated RNAi technology and offers the opportunity to bring treatments to patients globally. By partnering with Genentech — a major developer of biologic and targeted therapies — the program gains access to extensive clinical development and commercial infrastructure.
For Genentech, the agreement expands its pipeline of precision medicines, reflecting the broader pharmaceutical industry’s strategy of collaborating with specialized biotechnology firms to access emerging platforms.
While the specific disease target of the RNAi program has not been disclosed, the collaboration underscores continued momentum behind gene-silencing therapies, which are increasingly seen as a potential new class of treatments capable of addressing previously difficult-to-treat conditions.